Radiolabeling agent of antibody fragments for radionuclide therapy using At-211
| Project/Area Number |
26861025
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
Suzuki Hiroyuki 千葉大学, 薬学研究科(研究院), 助教 (00707648)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 211At / 抗体フラグメント / 代謝性リンカー / 内用放射線治療 / 刷子縁膜酵素 / Fab / アスタチン-211 |
|---|
| Outline of Final Research Achievements |
Since the half-life of 211At (7.2 h) is relatively short, antibody fragment which showed rapid biodistribution was used. When radiolabeled antibody fragments were injected into animals, persistent localization in kidney was observed. To solve this problem, I introduced cleavable linker which is recognized by renal brush border membrane enzymes. Due to this, 211At labeled Fab reduced renal radioactivity at early post injection. The molecular design would be useful for the application to clinical radiotherapy.
|
Report
(3 results)
Research Products
(3 results)
